Glaxo Muscular Dystrophy Drug Reaches Primary Objective in Study

GlaxoSmithKline Plc’s drisapersen achieved the primary objective of a mid-stage study, heating up competition with Sarepta Therapeutics Inc. in the race for a drug that could reverse the debilitating effects of Duchenne muscular dystrophy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.